Cargando…

BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up

(1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with can...

Descripción completa

Detalles Bibliográficos
Autores principales: Donze, Caroline, Min, Victoria, Ninove, Laetitia, de Lamballerie, Xavier, Revon Rivière, Gabriel, Verschuur, Arnauld, Saultier, Paul, André, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224057/
https://www.ncbi.nlm.nih.gov/pubmed/37243093
http://dx.doi.org/10.3390/vaccines11050989
_version_ 1785050086942703616
author Donze, Caroline
Min, Victoria
Ninove, Laetitia
de Lamballerie, Xavier
Revon Rivière, Gabriel
Verschuur, Arnauld
Saultier, Paul
André, Nicolas
author_facet Donze, Caroline
Min, Victoria
Ninove, Laetitia
de Lamballerie, Xavier
Revon Rivière, Gabriel
Verschuur, Arnauld
Saultier, Paul
André, Nicolas
author_sort Donze, Caroline
collection PubMed
description (1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with cancer. 2. To assess its efficacy in stimulating immunological response and in preventing severe COVID-19 disease. (3) Methods: Retrospective single-center study evaluating patients aged 8 to 22 years, with cancer, who underwent vaccination from January 2021 to June 2022. ELISA serologies and serum neutralization were collected monthly from the first injection. Serologies below 26 were considered negative, while those above 264 BAU/mL were considered positive and indicative of protection. Antibodies titers were considered positive above 20. Data on adverse events and infections were collected. (4) Results: 38 patients were included (M/F = 1.7, median age 16 years), of whom 63% had a localized tumor and 76% were undergoing treatment at the time of the first vaccination. Two or three vaccine injections were administered in 90% of patients. Adverse events were mainly systemic and not severe, except for seven grade 3 toxicities. Four cancer-related deaths were reported. Median serology was negative the month following the first vaccination and became protective during the third month. At 3 and 12 months, median serology was 1778 and 6437 BAU/mL, respectively. Serum neutralization was positive in 97% of the patients. COVID-19 infection occurred despite vaccination in 18%; all were mild forms. (5) Conclusions: In children and young adults with cancer, vaccination was well tolerated and conferred effective serum neutralization. COVID-19 infections were mild, and vaccine seroconversion persisted after 12 months in most patients. The value of additional vaccination should be further established.
format Online
Article
Text
id pubmed-10224057
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102240572023-05-28 BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up Donze, Caroline Min, Victoria Ninove, Laetitia de Lamballerie, Xavier Revon Rivière, Gabriel Verschuur, Arnauld Saultier, Paul André, Nicolas Vaccines (Basel) Article (1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with cancer. 2. To assess its efficacy in stimulating immunological response and in preventing severe COVID-19 disease. (3) Methods: Retrospective single-center study evaluating patients aged 8 to 22 years, with cancer, who underwent vaccination from January 2021 to June 2022. ELISA serologies and serum neutralization were collected monthly from the first injection. Serologies below 26 were considered negative, while those above 264 BAU/mL were considered positive and indicative of protection. Antibodies titers were considered positive above 20. Data on adverse events and infections were collected. (4) Results: 38 patients were included (M/F = 1.7, median age 16 years), of whom 63% had a localized tumor and 76% were undergoing treatment at the time of the first vaccination. Two or three vaccine injections were administered in 90% of patients. Adverse events were mainly systemic and not severe, except for seven grade 3 toxicities. Four cancer-related deaths were reported. Median serology was negative the month following the first vaccination and became protective during the third month. At 3 and 12 months, median serology was 1778 and 6437 BAU/mL, respectively. Serum neutralization was positive in 97% of the patients. COVID-19 infection occurred despite vaccination in 18%; all were mild forms. (5) Conclusions: In children and young adults with cancer, vaccination was well tolerated and conferred effective serum neutralization. COVID-19 infections were mild, and vaccine seroconversion persisted after 12 months in most patients. The value of additional vaccination should be further established. MDPI 2023-05-16 /pmc/articles/PMC10224057/ /pubmed/37243093 http://dx.doi.org/10.3390/vaccines11050989 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Donze, Caroline
Min, Victoria
Ninove, Laetitia
de Lamballerie, Xavier
Revon Rivière, Gabriel
Verschuur, Arnauld
Saultier, Paul
André, Nicolas
BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title_full BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title_fullStr BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title_full_unstemmed BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title_short BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
title_sort bnt162b2 covid-19 vaccines in children, adolescents and young adults with cancer—a 1-year follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224057/
https://www.ncbi.nlm.nih.gov/pubmed/37243093
http://dx.doi.org/10.3390/vaccines11050989
work_keys_str_mv AT donzecaroline bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT minvictoria bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT ninovelaetitia bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT delamballeriexavier bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT revonrivieregabriel bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT verschuurarnauld bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT saultierpaul bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup
AT andrenicolas bnt162b2covid19vaccinesinchildrenadolescentsandyoungadultswithcancera1yearfollowup